5-Amino-1MQ 50mg (60 Capsules)

Peptide Science research editorial team.

5-Amino-1MQ 50mg 60-Capsule Overview

5-Amino-1MQ (5-Amino-1-methylquinolinium) 50mg 60-Capsule from Peptide Science is a small-molecule research compound supplied in a 60-count sealed bottle at 50 milligrams per capsule. The compound is a selective, membrane-permeable inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), characterised in preclinical adipose-tissue and bioenergetics research for downstream effects on intracellular nicotinamide and NAD+ pools.

NNMT-Pathway Mechanism in Preclinical Models

NNMT methylates nicotinamide using S-adenosylmethionine as the methyl donor, consuming the substrate that would otherwise feed the NAD+ salvage pathway. By inhibiting NNMT, 5-Amino-1MQ has been characterised in preclinical research for the preservation of intracellular nicotinamide for downstream NAD+ synthesis, with reported effects on sirtuin-1 (SIRT1) activity in cultured adipocytes. The compound is studied alongside NMN (a direct NAD+ precursor) and JBSNF-000088 (a second NNMT inhibitor) in three-compound capsule blends. Browse related material in the metabolic peptide research catalogue.

Per-Capsule Specifications

For the three-compound research blend that combines 5-Amino-1MQ with NMN and JBSNF, see Longevity and Obesity Research 60-Capsule Blend.

Handling and Stability

The sealed capsule bottle stores at room temperature in a dry environment, away from direct sunlight and humidity, with the desiccant pouch retained in the cap. The reconstitution and concentration parameters used in any given research protocol are determined by the principal investigator. For paired research with the GH-fragment adipose-pathway compound, see AOD-9604 Peptide 6mg.

Quality and Shipping

Each batch passes HPLC and mass spectrometry at greater than 99 percent purity. A Certificate of Analysis accompanies every order. Material is prepared in a US laboratory under ISO 9001:2015-aligned quality systems and dispatched in standard sealed packaging via overnight or two-day courier.

For laboratory research and development use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease, including obesity or type 2 diabetes. Has not been evaluated by the U.S. Food and Drug Administration. Branded therapeutic GLP-1, GIP, and dual-agonist medicines (Ozempic, Wegovy, Mounjaro, Zepbound) are prescription-only medicines in the United States and are not the same as research-grade compounds supplied for in-vitro work. Purchasers acknowledge they are qualified researchers age 21 or older and accept responsibility for compliance with all applicable federal, state, and local laws.